glp-1 patent and Innovation Trends in and Weight Loss Drugs (2020–2025) As Novo's patent expires, GLP-1

Some patients find relief with digestive enzymes taken with meals, particularly those containing alpha-galactosidase (Beano) for carbohydrate digestion, though these have limited evidence and are not FDA-approved specifically for GLP-1 side effects

Lillys Oral GLP-1, Orforglipron, Delivers Weight Loss of Up to an Average of 27.3 Lbs in First of Two Pivotal Phase 3 Trials in Adults With Obesity

Furthermore, the group treated with GLP-1-R agonists experienced fewer headache days than the other group while the dose of acetazolamide was reduced

FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight